Standout Papers

An Official ATS/IDSA Statement: Diagnosis, Treatment, ... 1993 2026 2004 2015 4.1k
  1. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases (2007)
    David E. Griffith, Timothy R. Aksamit et al. American Journal of Respiratory and Critical Care Medicine
  2. Treatment of Multidrug-Resistant Tuberculosis (1993)
    Alastair J.J. Wood, Michael D. Iseman New England Journal of Medicine
  3. Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin (1993)
    Marian Goble, Michael D. Iseman et al. New England Journal of Medicine
  4. The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis (2005)
    Svetlana Gelperina, Kevin O. Kisich et al. American Journal of Respiratory and Critical Care Medicine

Immediate Impact

2 by Nobel laureates 27 from Science/Nature 62 standout
Sub-graph 1 of 19

Citing Papers

Engineering bacteria as interactive cancer therapies
2022 StandoutScience
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
3 intermediate papers

Works of Michael D. Iseman being referenced

The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
2005 Standout

Author Peers

Author Last Decade Papers Cites
Michael D. Iseman 5490 6565 2235 2316 69 8.9k
Fred M. Gordin 6291 6869 2043 2038 79 9.2k
Antonino Catanzaro 6930 8007 1807 2386 136 10.3k
Stephen J. Ruoss 3326 4620 1382 2225 61 7.1k
C. Fordham von Reyn 6347 7719 2163 2479 125 9.8k
Timothy R. Aksamit 3596 5170 1158 2301 83 6.7k
Kenneth N. Olivier 6073 8798 1662 4165 129 12.0k
Jakko van Ingen 5581 6602 1231 2722 231 8.0k
Gwen A. Huitt 3868 5481 1127 2852 28 6.2k
David E. Griffith 6984 9493 1720 4608 157 11.8k
William E. Dismukes 12010 12796 1094 1111 100 16.2k

All Works

Loading papers...

Rankless by CCL
2026